Researcher: Professor Caicun Zhou, Shanghai Pulmonary Hospital Professor Nong Xu, The First Affiliated Hospital, School of Medicine, Zhejiang University Topic: Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in first-line advanced squamous non-small cell lung cancer (sqNSCLC): initial results from a phase Ib study Researcher: Professor Chenyu Mao, Professor Nong Xu, The First Affiliated Hospital, School of Medicine, Zhejiang University Topic: Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: preliminary results from a phase Ib study A brief summary of the studies is as follows:
("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, today announced that the company will present clinical data from multiple trials in relation to TYVYT ® (sintilimab injection), Pemazyre ® (pemigatinib), olverembatinib (BCL ABL TIK), IBI110 (anti-LAG-3 monoclonal antibody), IBI376 (PI3Kδ inhibitor), IBI344 (ROS1/NTRK TKI), IBI351 (KRAS G12C inhibitor) and IBI319 (PD-1/CD137 bispecific antibody) at the 2022 American Society of Clinical Oncology (ASCO) annual meeting, June 3-7, 2022. SAN FRANCISCO and SUZHOU, China, /PRNewswire/ - Innovent Biologics, Inc.